JP6557331B2 - Ｆｓｈｒのモジュレータとしてのピラゾール化合物およびその使用 - Google Patents

Ｆｓｈｒのモジュレータとしてのピラゾール化合物およびその使用 Download PDF

Info

Publication number
JP6557331B2
JP6557331B2 JP2017519756A JP2017519756A JP6557331B2 JP 6557331 B2 JP6557331 B2 JP 6557331B2 JP 2017519756 A JP2017519756 A JP 2017519756A JP 2017519756 A JP2017519756 A JP 2017519756A JP 6557331 B2 JP6557331 B2 JP 6557331B2
Authority
JP
Japan
Prior art keywords
compound
methyl
certain embodiments
methoxy
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017519756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524733A (ja
JP2017524733A5 (https=
Inventor
ヘンリー ユ，
ヘンリー ユ，
チャンヘ チ，
チャンヘ チ，
ポール テンペスト，
ポール テンペスト，
セルバラジ ジー． ナタラジャ，
セルバラジ ジー． ナタラジャ，
スティーブン エス． パルマー，
スティーブン エス． パルマー，
Original Assignee
トコフェレックス， インコーポレイテッド
トコフェレックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トコフェレックス， インコーポレイテッド, トコフェレックス， インコーポレイテッド filed Critical トコフェレックス， インコーポレイテッド
Publication of JP2017524733A publication Critical patent/JP2017524733A/ja
Publication of JP2017524733A5 publication Critical patent/JP2017524733A5/ja
Application granted granted Critical
Publication of JP6557331B2 publication Critical patent/JP6557331B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017519756A 2014-06-23 2014-12-22 Ｆｓｈｒのモジュレータとしてのピラゾール化合物およびその使用 Expired - Fee Related JP6557331B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/080519 2014-06-23
PCT/CN2014/080519 WO2015196335A1 (en) 2014-06-23 2014-06-23 Pyrazole compounds as modulators of fshr and uses thereof
PCT/CN2014/094459 WO2015196759A1 (en) 2014-06-23 2014-12-22 Pyrazole compounds as modulators of fshr and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019129171A Division JP2019196375A (ja) 2014-06-23 2019-07-11 Ｆｓｈｒのモジュレータとしてのピラゾール化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2017524733A JP2017524733A (ja) 2017-08-31
JP2017524733A5 JP2017524733A5 (https=) 2018-01-18
JP6557331B2 true JP6557331B2 (ja) 2019-08-07

Family

ID=54936412

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017519756A Expired - Fee Related JP6557331B2 (ja) 2014-06-23 2014-12-22 Ｆｓｈｒのモジュレータとしてのピラゾール化合物およびその使用
JP2019129171A Pending JP2019196375A (ja) 2014-06-23 2019-07-11 Ｆｓｈｒのモジュレータとしてのピラゾール化合物およびその使用
JP2020191715A Pending JP2021038245A (ja) 2014-06-23 2020-11-18 Ｆｓｈｒのモジュレータとしてのピラゾール化合物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019129171A Pending JP2019196375A (ja) 2014-06-23 2019-07-11 Ｆｓｈｒのモジュレータとしてのピラゾール化合物およびその使用
JP2020191715A Pending JP2021038245A (ja) 2014-06-23 2020-11-18 Ｆｓｈｒのモジュレータとしてのピラゾール化合物およびその使用

Country Status (12)

Country Link
US (3) US10208055B2 (https=)
EP (1) EP3157929B1 (https=)
JP (3) JP6557331B2 (https=)
KR (1) KR102416279B1 (https=)
CN (1) CN106573937B (https=)
AU (3) AU2014398875B2 (https=)
CA (1) CA2955415A1 (https=)
DK (1) DK3157929T3 (https=)
ES (1) ES2972131T3 (https=)
MX (1) MX389867B (https=)
RU (1) RU2752173C2 (https=)
WO (2) WO2015196335A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021038245A (ja) * 2014-06-23 2021-03-11 アレス トレーディング ソシエテ アノニム Ｆｓｈｒのモジュレータとしてのピラゾール化合物およびその使用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106967076A (zh) * 2017-03-30 2017-07-21 河南师范大学 一种具有6h‑二苯并吡喃结构化合物及其制备方法
CN106977523A (zh) * 2017-03-30 2017-07-25 河南师范大学 具有苯基并四氢吡咯结构的fshr拮抗剂及其制备方法
CN106866692A (zh) * 2017-03-30 2017-06-20 毛阿龙 具有苯并1,4‑二氧杂环己二烯酮结构的fshr拮抗剂的制备方法
ES2971712T3 (es) * 2017-12-22 2024-06-06 Hibercell Inc Derivados de cromenopiridina como inhibidores de la fosfatidilinositol fosfato cinasa
MY208400A (en) 2018-05-03 2025-05-07 Shanghai hengrui pharmaceutical co ltd Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof
TW202112784A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
CN113754678B (zh) * 2020-06-02 2023-03-10 江苏恒瑞医药股份有限公司 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用
WO2022007924A1 (zh) * 2020-07-09 2022-01-13 江苏恒瑞医药股份有限公司 氧杂氮杂双环类衍生物、其制备方法及其在医药上的应用
TW202214656A (zh) * 2020-07-29 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 氧氮雜環螺環衍生物、其製備方法及其醫藥用途
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
IL319132A (en) * 2022-08-26 2025-04-01 Celmatix Inc New FSHR modulators and their uses
JP2025535050A (ja) * 2022-10-05 2025-10-22 ラディオネティクス オンコロジー，インク． 卵胞刺激ホルモン受容体（ｆｓｈｒ）を標的とした治療薬およびその使用
EP4676591A2 (en) 2023-03-08 2026-01-14 Ferring B.V. Small molecule fsh receptor modulators
WO2024263803A2 (en) * 2023-06-21 2024-12-26 Celmatix Inc. Novel modulators of fshr and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814586D0 (en) * 1988-06-20 1988-07-27 Erba Carlo Spa Tricyclic 3-oxo-propanenitrile derivatives & process for their preparation
EP1307193A1 (en) 2000-07-27 2003-05-07 Affymax Research Institute Agonists of follicle stimulating hormone activity
ATE363473T1 (de) * 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
KR20050096956A (ko) 2003-02-07 2005-10-06 다이이찌 세이야꾸 가부시기가이샤 피라졸 유도체
US7687623B2 (en) * 2005-05-12 2010-03-30 Wyeth Llc Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (FSH-R) antagonists
WO2008035356A2 (en) * 2006-09-20 2008-03-27 Glenmark Pharmaceuticals Limited Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
IT1393930B1 (it) * 2009-02-25 2012-05-17 Neuroscienze Pharmaness S C A R L Composti farmaceutici
IT1394400B1 (it) * 2009-02-25 2012-06-15 Neuroscienze Pharmaness S C Ar L Composizioni farmaceutiche
TWI461426B (zh) * 2009-05-27 2014-11-21 Merck Sharp & Dohme （二氫）咪唑並異〔５，１－ａ〕喹啉類
KR20130049766A (ko) * 2009-11-13 2013-05-14 메르크 세로노 에스. 에이. 트리사이클릭 피라졸 아민 유도체
CA2837524C (en) 2011-07-01 2019-08-20 Merck Patent Gmbh Dihydropyrazoles
EP2734517B1 (en) 2011-07-18 2017-08-30 Merck Patent GmbH Benzamides
WO2013106409A1 (en) 2012-01-10 2013-07-18 Merck Patent Gmbh Benzamide derivatives as modulators of the follicle stimulating hormone
EP2812320B1 (en) 2012-02-08 2018-03-07 Merck Patent GmbH Deuterated thiazolidinone analogues as agonists for follicle stimulating hormone receptor
WO2014209980A1 (en) * 2013-06-24 2014-12-31 Merck Patent Gmbh Pyrazole compounds as modulators of fshr and uses thereof
JP6523267B2 (ja) 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用
WO2015196335A1 (en) 2014-06-23 2015-12-30 Tocopherx, Inc. Pyrazole compounds as modulators of fshr and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021038245A (ja) * 2014-06-23 2021-03-11 アレス トレーディング ソシエテ アノニム Ｆｓｈｒのモジュレータとしてのピラゾール化合物およびその使用

Also Published As

Publication number Publication date
RU2017101829A (ru) 2018-07-27
EP3157929B1 (en) 2023-12-13
EP3157929A1 (en) 2017-04-26
KR102416279B1 (ko) 2022-07-01
AU2014398875B2 (en) 2019-11-21
WO2015196335A1 (en) 2015-12-30
RU2017101829A3 (https=) 2018-08-30
US10941152B2 (en) 2021-03-09
AU2020201240A1 (en) 2020-03-12
RU2752173C2 (ru) 2021-07-23
US20220402929A1 (en) 2022-12-22
WO2015196759A1 (en) 2015-12-30
MX2017000182A (es) 2017-06-30
KR20170033314A (ko) 2017-03-24
JP2017524733A (ja) 2017-08-31
US20170253605A1 (en) 2017-09-07
CN106573937B (zh) 2022-02-11
EP3157929A4 (en) 2018-03-07
AU2021204814A1 (en) 2021-08-05
ES2972131T3 (es) 2024-06-11
JP2019196375A (ja) 2019-11-14
CN106573937A (zh) 2017-04-19
MX389867B (es) 2025-03-20
AU2021204814B2 (en) 2023-07-20
JP2021038245A (ja) 2021-03-11
US20190135823A1 (en) 2019-05-09
CA2955415A1 (en) 2015-12-30
US10208055B2 (en) 2019-02-19
DK3157929T3 (da) 2024-02-05
AU2014398875A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
JP6557331B2 (ja) Ｆｓｈｒのモジュレータとしてのピラゾール化合物およびその使用
JP6625973B2 (ja) Ｆｓｈｒの調節剤としてのピラゾール化合物及びその使用
JP6523267B2 (ja) Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用
HK1218757B (zh) 用作卵泡刺激素受体调节剂的吡唑化合物及其用途
NZ714201B2 (en) Pyrazole compounds as modulators of fshr and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190711

R150 Certificate of patent or registration of utility model

Ref document number: 6557331

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees